Clinical Trial Update: Optimizing Pazopanib Exposure in RCC Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial in locally advanced or metastatic renal cell carcinoma evaluating pazopanib exposure has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e. | Conditions: Locally Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Status: TERMINATED